BLAST demonstrates higher prognostic accuracy for survival than CPSS in Chinese patients with chronic myelomonocytic leukemia.

Blood Cancer J · 2026 · PMC13276038 · PMID 42310291

Europe PMC DOI

hedged sentences

0.0001

closest p · 0.0× alpha

0.0001

boldest claim

The sentences

highly significantP < 0.0001actually significant

The mOS was NR, 24 months (95% CI 16.53–31.47), and 12 months (95% CI 9.23–14.77), respectively, with highly significant differences across BLAST-mol risk categories ( P < 0.0001; Fig. 1D ).

also in 132,142 other papers

showed a trendno p-value reported

WBC ≥ 13 × 10 9 /L (HR 1.57, 95% CI 0.98–2.53, P = 0.064) and high molecular risk (HR 3.21, 95% CI 0.99–10.42, P = 0.052) showed a trend toward statistical significance, and thus were included together in the multivariate analysis.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.